Sort
130,381 grants matching “hiv”
Multidisciplinary Collaborative Research in NIDDK Program Area Diseases
$1,182,595James Balow · Diabetes, Digestive, Kidney Diseases · Z01 · FY2007 · DK
PLCO Trial Etiologic and Early Marker Study
$1,182,573Steven Moore · Division Of Cancer Epidemiology And Genetics · ZIA · FY2024 · CA
National Neurological AIDS Bank
$1,182,485Elyse J Singer · University Of California Los Angeles · U24 · FY2013 · MH
STRUCTURE-BASED DESIGN PARADIGM:HIV Tat.PCAF INHIBITORS
$1,182,190Mount Sinai School Of Medicine Of Nyu · P01 · FY2003 · GM
California NeuroAIDS Tissue Network
$1,182,137David J Moore · University Of California, San Diego · U24 · FY2015 · MH
The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP)
$1,181,637Charles W. Flexner · Johns Hopkins University · R24 · FY2025 · AI
Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing
$1,181,599Mark Middleton · Starks Associates, Inc. · N01 · FY2022 · AI
HIV & AIDS PREVENTION AND PALLIATIVE CARE FOR TEACHERS, ORPHANS AND VUNERABLE
$1,181,591Nomfundo Mkhulisi · South African Democratic Teacher'S Union · U2G · FY2011 · PS
NINDS Quantitative MRI Core Facility
$1,181,570Govind Nair · National Institute Of Neurological Disorders And Stroke · ZIC · FY2025 · NS
Preclinical Development of HIV-1 Vif Antagonists
$1,181,526Mario Stevenson · University Of Miami School Of Medicine · P01 · FY2016 · MH
Metabolic and Immunologic Effects of Meditation
$1,181,122Frederick M Hecht · University Of California, San Francisco · P01 · FY2012 · AT
Single Cell Transcriptomics of the Opioid Use Disorder and HIV Syndemic in the Human Brain
$1,181,109Christine Cheng · J. Craig Venter Institute, Inc. · UM1 · FY2020 · DA
Virologic Correlates of Heterosexual Transmission
$1,181,079Eric Hunter · Emory University · R01 · FY2020 · AI
HEMATOPOIETIC STEM CELL GROWTH AND ENGRAFTMENT
$1,180,821Univ Of Massachusetts Med Sch Worcester · P01 · FY2000 · HL
Molecular Genetics Of Mammalian Retrovirus Replication
$1,180,742Judith G Levin · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2012 · HD
PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
$1,180,713Serena Patricia Koenig · Brigham And Women'S Hospital · U01 · FY2023 · AI
Drugs of Abuse Affecting AIDS Pathogenesis
$1,180,615Thomas J Rogers · Temple Univ Of The Commonwealth · P01 · FY2012 · DA
Adjuvant Development Program in the context of vaccines to protect against Y. pestis and Shigella.
$1,180,599University Of Maryland Baltimore · N01 · FY2018 · AI
Center on Intersystem Regulation by Drugs of Abuse
$1,180,557Ellen M Unterwald · Temple Univ Of The Commonwealth · P30 · FY2013 · DA
Innovations for screening and prognosis in HIV+ cancers including Kaposi sarcoma, cervical cancer, and lymphoma in Malawi and South Africa
$1,180,460Blossom A Damania · Univ Of North Carolina Chapel Hill · U54 · FY2020 · CA
Turning off HIV White Noise: Switching from Long-Lived to Short-Lived Reservoir
$1,180,430Elena Martinelli · Northwestern University At Chicago · R01 · FY2024 · AI
The Johns Hopkins Fogarty AIDS International Training and Research Program
$1,180,170Chris Beyrer · Johns Hopkins University · D43 · FY2007 · TW
The HIV and Alcohol Research center focused on Polypharmacy (HARP)
$1,180,102Amy Caroline Justice · Yale University · P01 · FY2023 · AA
Vaccine and adjuvant Clinical GMP product development and DNA Technology platform enhancements
$1,180,089Trevor Smith · Wistar Institute · U19 · FY2023 · AI
Molecular Mechanisms Of Human Immunodeficiency Virus Trans-regulatory Proteins
$1,180,061Kuan-Teh Jeang · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI